Difference between revisions of "Carboplatin (Paraplatin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "==Diseases for which it is established==" to "==Diseases for which it is established ''(work in progress)''==")
m
Line 37: Line 37:
 
*[[Hodgkin lymphoma]]
 
*[[Hodgkin lymphoma]]
 
*[[Low-grade glioma]]
 
*[[Low-grade glioma]]
 +
**[[Low-grade glioma, pediatric]]
 
*[[Mantle cell lymphoma]]
 
*[[Mantle cell lymphoma]]
 
*[[Medulloblastoma]]
 
*[[Medulloblastoma]]
Line 147: Line 148:
 
[[Category:Hodgkin lymphoma medications]]
 
[[Category:Hodgkin lymphoma medications]]
 
[[Category:Low-grade glioma medications]]
 
[[Category:Low-grade glioma medications]]
 +
[[Category:Low-grade glioma, pediatric medications]]
 
[[Category:Mantle cell lymphoma medications]]
 
[[Category:Mantle cell lymphoma medications]]
 
[[Category:Medulloblastoma medications]]
 
[[Category:Medulloblastoma medications]]

Revision as of 22:16, 16 March 2023

General information

Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]

Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Dosing information

Calvert formula

  • Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. link to original article contains verified formula PubMed

Diseases for which it is established (work in progress)

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 3/3/1989: Initial approval as palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin. (Based on SWOG 8412 and Swenerton et al. 1992)

Also known as

  • Code name: JM8
  • Brand names:
Synonyms
Biocarb Biocarbo Bioplatinex Biovinate Blastocarb Bonaplatin Boplatex Carbo
Carbokem Carbomedac Carbomerck Carboplat Carboplatine Carboplatino Carboplatinum Carbosin
Carbotanil Carbotec Carbotinol Careptin Carplan Carplanil Carpsol Crobextin
Cycloplatin Cycloplatinum Emorzim Erbakar Ercar Fauldcarbo Ifacap Kemocarb
Megaplatin Nealorin Neocarb Neocarbo Oncocarb Paraplatin Paraplatine Pharmaplatin
Platamine CS Platinwas Ribocarbo Tecnocarb Vancel CBDCA

References